2,2-Dimethyl-1-(4-methylpiperazin-1-yl)butan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2,2-Dimethyl-1-(4-methylpiperazin-1-yl)butan-1-one
• 化学式: C₁₁H₂₂N₂O
• 分子量: 198.31
• InChiKey: CIJNNGNOUMPWPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE
  申请人：BIOWAY., INC

  公开号：US20200157048A1

  公开（公告）日：2020-05-21

  The present application relates to a novel pentadienoyl compound and a pharmaceutical composition including the same. The pentadienoyl compound of the present application may be used to prevent or treat fatty liver and fatty liver-related disease by inhibiting lipogenesis and lipid accumulation in cells and activating lipid metabolism. In addition, the pentadienoyl compound of the present application may increase a SIRT1 expression level in cells or SIRT1 activity, and thus may be used to prevent or treat a SIRT1-mediated disease. In addition, the pentadienoyl compound of the present application may reduce a CK2 expression level in cells or CK2 activity, and thus may be used to prevent or treat a CK2-mediated disease.

  本申请涉及一种新型的戊二烯酰化合物和包括该化合物的药物组合物。本申请的戊二烯酰化合物可用于通过抑制细胞内脂肪生成和脂质积累，激活脂质代谢，预防或治疗脂肪肝和脂肪肝相关疾病。此外，本申请的戊二烯酰化合物可能增加细胞中SIRT1的表达水平或SIRT1的活性，因此可用于预防或治疗SIRT1介导的疾病。此外，本申请的戊二烯酰化合物可能降低细胞中CK2的表达水平或CK2的活性，因此可用于预防或治疗CK2介导的疾病。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson Howard John

  公开号：US20070219206A1

  公开（公告）日：2007-09-20

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了一些化合物和含有这些化合物的制药组合物，这些化合物可以调节5-脂氧合酶激活蛋白（FLAP）的活性。本文还描述了使用这种FLAP调节剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖于白三烯或介导白三烯的疾病或病症。
• Pyrrole derivatives as PLK1 inhibitors
  申请人：SENTINEL ONCOLOGY LIMITED

  公开号：US11208405B2

  公开（公告）日：2021-12-28

  The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from various substituents: R2 is selected from hydrogen and a C1-4 hydrocarbon group; R3 is selected from hydrogen and a C1-4 hydrocarbon group; R4 is selected from various substituents; R5 is selected from various substituents; Ar2 is an optionally substituted phenyl, pyridyl or pyridone group; R6 is a group Q1-Ra—Rb; Q1 is absent or is a C1-3 saturated hydrocarbon linker; Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc; Rb is selected from hydrogen and various substituents; and R7 is selected from R4. The compounds are useful in the treatment of cancers.

  本发明提供了式 (3) 的化合物： 或其药学上可接受的盐或同系物，其中 Z 是一个 5 元杂芳基环，含有一个或两个氮环成员，可选地还含有一个选自 N 和 O 的杂原子环成员； 环 X 是苯环或吡啶环； 环 Y 是苯、吡啶、噻吩或呋喃环； Ar1 是任选取代的苯、吡啶、噻吩或呋喃环； m 为 0、1 或 2； n 为 0、1 或 2； R1 选自各种取代基： R2 选自氢和 C1-4 烃基； R3 选自氢和 C1-4 烃基； R4 选自各种取代基； R5 选自各种取代基； Ar2 是任选取代的苯基、吡啶基或吡啶酮基团； R6 是 Q1-Ra-Rb 基团； Q1 不存在或为 C1-3 饱和烃连接体； Ra 选自 O、C(O)、C(O)O、CONRc、N(Rc)CO、N(Rc)CONRc、NRc 和 SO2NRc； Rb 选自氢和各种取代基； R7 选自 R4。 这些化合物可用于治疗癌症。
• PYRROLE DERIVATIVES AS PLK1 INHIBITORS
  申请人：SENTINEL ONCOLOGY LIMITED

  公开号：US20200247796A1

  公开（公告）日：2020-08-06

  The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar 1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R 1 is selected from various substituents: R 2 is selected from hydrogen and a C 1-4 hydrocarbon group; R 3 is selected from hydrogen and a C 1-4 hydrocarbon group; R 4 is selected from various substituents; R 5 is selected from various substituents; Ar 2 is an optionally substituted phenyl, pyridyl or pyridone group; R 6 is a group Q 1 -R a —R b ; Q 1 is absent or is a C 1-3 saturated hydrocarbon linker; R a is selected from O; C(O); C(O)O; CONR c ; N(R c )CO; N(R c )CONR c , NR c ; and SO 2 NR c ; R b is selected from hydrogen and various substituents; and R 7 is selected from R 4 . The compounds are useful in the treatment of cancers.
• 10-(DI(PHENYL)METHYL)-4-HYDROXY-8,9,9A,10-TETRAHYDRO-7H-PYRROLO[1 ',2':4,5]PYRAZINO[1,2-B]PYRIDAZINE-3,5-DIONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE ORTHOMYXOVIRUS REPLICATION FOR TREATING INFLUENZA
  申请人：Novartis AG

  公开号：US20200407366A1

  公开（公告）日：2020-12-31

  The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.